Quarterly report pursuant to Section 13 or 15(d)

Interim Segment Information (Tables)

v2.4.0.6
Interim Segment Information (Tables)
9 Months Ended
Dec. 31, 2012
Segment Reporting [Abstract]  
Segment information
Segment information for the three and nine months ended December 31, 2012 and 2011 is set forth below: 
 
Three months ended December 31, 2012
(in thousands)
Westell
 
CNS
 
Unallocated
 
Total
Revenue
$
8,873

 
$
55

 
$

 
$
8,928

Cost of goods sold
5,783

 
2

 

 
5,785

Gross profit
3,090

 
53

 

 
3,143

Gross margin
34.8
%
 
96.4
%
 

 
35.2
%
Operating expenses:
 
 
 
 
 
 
 
Sales and marketing
1,862

 
(55
)
 

 
1,807

Research and development
1,331

 
423

 

 
1,754

General and administrative
938

 
(11
)
 
1,197

 
2,124

Restructuring

 

 

 

Intangible amortization
234

 
2

 

 
236

Total operating expenses
4,365

 
359

 
1,197

 
5,921

Operating income (loss)
$
(1,275
)
 
$
(306
)
 
(1,197
)
 
(2,778
)
Other income
 
 
 
 
43

 
43

Income (loss) before income taxes and discontinued operations
 
 
 
 
(1,154
)
 
(2,735
)
Income tax benefit (expense)
 
 
 
 
1,399

 
1,399

Net income (loss) from continuing operations
 
 
 
 
$
245

 
$
(1,336
)
 
 
 
 
 
 
 
 
 
Three months ended December 31, 2011
(in thousands)
Westell
 
CNS
 
Unallocated
 
Total
Revenue
$
7,674

 
$
6,718

 
$

 
$
14,392

Cost of goods sold
5,024

 
5,105

 

 
10,129

Gross profit
2,650

 
1,613

 

 
4,263

Gross margin
34.5
%
 
24.0
%
 

 
29.6
%
Operating expenses:
 
 
 
 
 
 
 
Sales and marketing
1,269

 
145

 

 
1,414

Research and development
1,223

 
574

 

 
1,797

General and administrative
649

 
200

 
858

 
1,707

Restructuring

 
(2
)
 

 
(2
)
Intangible amortization
135

 
1

 

 
136

Total operating expenses
3,276

 
918

 
858

 
5,052

Operating income (loss)
$
(626
)
 
$
695

 
(858
)
 
(789
)
Other income
 
 
 
 
106

 
106

Interest (expense)
 
 
 
 
(37
)
 
(37
)
Income (loss) before income taxes and discontinued operations
 
 
 
 
(789
)
 
(720
)
Income tax benefit (expense)
 
 
 
 
268

 
268

Net income (loss) from continuing operations
 
 
 
 
$
(521
)
 
$
(452
)

 
Nine months ended December 31, 2012
(in thousands)
Westell
 
CNS
 
Unallocated
 
Total
Revenue
$
28,145

 
$
1,235

 
$

 
$
29,380

Cost of goods sold
18,833

 
160

 

 
18,993

Gross profit
9,312

 
1,075

 

 
10,387

Gross margin
33.1
%
 
87.0
%
 

 
35.4
%
Operating expenses:
 
 
 
 
 
 
 
Sales and marketing
5,568

 
(53
)
 

 
5,515

Research and development
4,216

 
1,299

 

 
5,515

General and administrative
3,232

 
531

 
3,605

 
7,368

Restructuring
149

 

 

 
149

Intangible amortization
652

 
4

 

 
656

Total operating expenses
13,817

 
1,781

 
3,605

 
19,203

Operating income (loss)
$
(4,505
)
 
$
(706
)
 
(3,605
)
 
(8,816
)
Other income
 
 
 
 
134

 
134

Income (loss) before income taxes and discontinued operations
 
 
 
 
(3,471
)
 
(8,682
)
Income tax benefit (expense)
 
 
 
 
3,431

 
3,431

Net income (loss) from continuing operations
 
 
 
 
$
(40
)
 
$
(5,251
)
 
 
 
 
 
 
 
 
 
Nine months ended December 31, 2011
(in thousands)
Westell
 
CNS
 
Unallocated
 
Total
Revenue
$
32,920

 
$
25,401

 
$

 
$
58,321

Cost of goods sold
19,830

 
19,641

 

 
39,471

Gross profit
13,090


5,760

 

 
18,850

Gross margin
39.8
%
 
22.7
%
 

 
32.3
%
Operating expenses:
 
 
 
 
 
 
 
Sales and marketing
4,197

 
911

 

 
5,108

Research and development
3,829

 
2,036

 

 
5,865

General and administrative
2,071

 
751

 
2,803

 
5,625

Restructuring

 
275

 

 
275

Intangible amortization
410

 
3

 

 
413

Total operating expenses
10,507

 
3,976

 
2,803

 
17,286

Operating income (loss)
$
2,583

 
$
1,784

 
(2,803
)
 
1,564

Gain on CNS asset sale
 
 
 
 
31,654

 
31,654

Other income
 
 
 
 
201

 
201

Interest (expense)
 
 
 
 
(42
)
 
(42
)
Income (loss) before income taxes and discontinued operations
 
 
 
 
29,010

 
33,377

Income tax benefit (expense)
 
 
 
 
(11,108
)
 
(11,108
)
Net income (loss) from continuing operations
 
 
 
 
$
17,902

 
$
22,269